Trader consensus implies an 88.5% probability against a new pandemic in 2026, driven by the absence of any novel pathogen achieving sustained human-to-human transmission at a global scale, per WHO and CDC surveillance data through mid-April. Key candidates like H5N1 avian influenza show only sporadic human cases—over 890 globally since 2003, with no efficient person-to-person spread—and mpox clade I remains largely confined to Africa, with 179,000+ cases since 2022 but low international risk. Other monitored threats, including Marburg, dengue, and emerging viruses like influenza D, have not escalated beyond regional outbreaks. Enhanced global preparedness post-COVID-19, including vaccine stockpiles, bolsters this view, though inherent forecasting uncertainty persists; upcoming WHO epidemiological updates and CDC outbreak reports could shift sentiment if transmission dynamics change.